Remdesivir: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Loading dose: 200 mg IV administered on day 1 | |||
*Maintenance dose: 100 mg IV daily for duration of hospitalization, up to 10 days<ref>Gilead Sciences. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04292899. NLM identifier: NCT04292899. Accessed March 21, 2020.</ref> | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Not studied in pediatric patients | |||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *No data | ||
===Lactation risk=== | ===Lactation risk=== | ||
* | *No data | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: Unknown | ||
*Pediatric: | *Pediatric: Unknown | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: | *Adult: Unknown | ||
*Pediatric: | *Pediatric: Unknown | ||
==Contraindications== | ==Contraindications== | ||
| Line 31: | Line 32: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Unknown | |||
===Common=== | ===Common=== | ||
*Unknown | |||
==Pharmacology== | ==Pharmacology== | ||
Revision as of 23:04, 21 March 2020
Administration
- Type: Antiviral
- Dosage Forms: 100 mg, 200 mg
- Routes of Administration: IV
- Common Trade Names: N/a
Adult Dosing
- Loading dose: 200 mg IV administered on day 1
- Maintenance dose: 100 mg IV daily for duration of hospitalization, up to 10 days[1]
Pediatric Dosing
- Not studied in pediatric patients
Special Populations
Pregnancy Rating
- No data
Lactation risk
- No data
Renal Dosing
- Adult: Unknown
- Pediatric: Unknown
Hepatic Dosing
- Adult: Unknown
- Pediatric: Unknown
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Unknown
Common
- Unknown
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ Gilead Sciences. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04292899. NLM identifier: NCT04292899. Accessed March 21, 2020.